Titre : Vincristine

Vincristine : Questions médicales fréquentes

Termes MeSH sélectionnés :

SEER Program

Questions fréquentes et termes MeSH associés

Diagnostic 2

#1

Comment la vincristine est-elle utilisée dans le diagnostic ?

La vincristine n'est pas un outil de diagnostic, mais un traitement pour des cancers diagnostiqués.
Vincristine Cancer Diagnostic
#2

Quels tests précèdent l'administration de vincristine ?

Des tests sanguins et des examens d'imagerie sont effectués pour évaluer la maladie.
Tests de laboratoire Imagerie médicale Vincristine

Symptômes 2

#1

Quels sont les effets secondaires de la vincristine ?

Les effets secondaires incluent neuropathie, constipation, et fatigue.
Effets secondaires Neuropathie Vincristine
#2

La vincristine cause-t-elle des douleurs ?

Oui, elle peut provoquer des douleurs neuropathiques chez certains patients.
Douleur Neuropathie Vincristine

Prévention 2

#1

Peut-on prévenir les effets secondaires de la vincristine ?

Des mesures préventives incluent une surveillance étroite et des médicaments pour les symptômes.
Prévention Effets secondaires Vincristine
#2

Y a-t-il des recommandations avant le traitement par vincristine ?

Oui, une évaluation médicale complète est recommandée avant le traitement.
Évaluation médicale Vincristine Préparation au traitement

Traitements 2

#1

Avec quels médicaments la vincristine est-elle souvent combinée ?

Elle est souvent combinée avec la prednisone et d'autres agents chimiothérapeutiques.
Chimiothérapie Vincristine Prednisone
#2

Comment la vincristine est-elle administrée ?

La vincristine est administrée par voie intraveineuse, généralement en cycle.
Administration intraveineuse Vincristine Chimiothérapie

Complications 2

#1

Quelles complications peuvent survenir avec la vincristine ?

Des complications incluent des infections, des troubles neurologiques et des problèmes gastro-intestinaux.
Complications Infections Vincristine
#2

La vincristine peut-elle causer des problèmes cardiaques ?

Bien que rare, des problèmes cardiaques peuvent survenir, nécessitant une surveillance.
Problèmes cardiaques Vincristine Surveillance médicale

Facteurs de risque 2

#1

Qui est à risque d'effets indésirables de la vincristine ?

Les patients âgés et ceux avec des antécédents de neuropathie sont à risque accru.
Facteurs de risque Neuropathie Vincristine
#2

Les antécédents médicaux influencent-ils le traitement par vincristine ?

Oui, des antécédents de maladies neurologiques peuvent affecter le traitement.
Antécédents médicaux Vincristine Neurologie
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Vincristine : Questions médicales les plus fréquentes", "headline": "Vincristine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Vincristine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-27", "dateModified": "2025-02-21", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Vincristine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Alcaloïdes de Vinca", "url": "https://questionsmedicales.fr/mesh/D014748", "about": { "@type": "MedicalCondition", "name": "Alcaloïdes de Vinca", "code": { "@type": "MedicalCode", "code": "D014748", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.496.500.500.681.827" } } }, "about": { "@type": "MedicalCondition", "name": "Vincristine", "alternateName": "Vincristine", "code": { "@type": "MedicalCode", "code": "D014750", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Wenjian Yang", "url": "https://questionsmedicales.fr/author/Wenjian%20Yang", "affiliation": { "@type": "Organization", "name": "Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA." } }, { "@type": "Person", "name": "Deqing Pei", "url": "https://questionsmedicales.fr/author/Deqing%20Pei", "affiliation": { "@type": "Organization", "name": "Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA." } }, { "@type": "Person", "name": "Cheng Cheng", "url": "https://questionsmedicales.fr/author/Cheng%20Cheng", "affiliation": { "@type": "Organization", "name": "Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA." } }, { "@type": "Person", "name": "William E Evans", "url": "https://questionsmedicales.fr/author/William%20E%20Evans", "affiliation": { "@type": "Organization", "name": "Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA." } }, { "@type": "Person", "name": "Richard H Ho", "url": "https://questionsmedicales.fr/author/Richard%20H%20Ho", "affiliation": { "@type": "Organization", "name": "Vanderbilt University Medical Center, Nashville, TN." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The epidemiology and prognosis of patients with primary gastric T-cell lymphoma in the SEER program.", "datePublished": "2022-06-13", "url": "https://questionsmedicales.fr/article/35698430", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/cam4.4936" } }, { "@type": "ScholarlyArticle", "name": "Soft-tissue Sarcoma Survival in the US Military Health System: Comparison With the SEER Program.", "datePublished": "2022-06-21", "url": "https://questionsmedicales.fr/article/35727910", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.5435/JAAOSGlobal-D-22-00122" } }, { "@type": "ScholarlyArticle", "name": "Risk prediction of second primary malignancies in patients after rectal cancer: analysis based on SEER Program.", "datePublished": "2023-10-12", "url": "https://questionsmedicales.fr/article/37828423", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12876-023-02974-2" } }, { "@type": "ScholarlyArticle", "name": "Specific causes of death among patients with cardiac sarcoma in the United States-An analysis of The Surveillance, Epidemiology, and End Results (SEER) Program.", "datePublished": "2022-08-18", "url": "https://questionsmedicales.fr/article/35979675", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jocs.16857" } }, { "@type": "ScholarlyArticle", "name": "Comparative overall survival analysis of chordomas of the base of the skull from the Surveillance, Epidemiology, and End Results (SEER) program between 2000 and 2020.", "datePublished": "2024-09-25", "url": "https://questionsmedicales.fr/article/39320522", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10143-024-02815-0" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Indolizine", "item": "https://questionsmedicales.fr/mesh/D007212" }, { "@type": "ListItem", "position": 6, "name": "Indolizidines", "item": "https://questionsmedicales.fr/mesh/D054836" }, { "@type": "ListItem", "position": 7, "name": "Alcaloïdes indoliques", "item": "https://questionsmedicales.fr/mesh/D026121" }, { "@type": "ListItem", "position": 8, "name": "Alcaloïdes formés par condensation de sécologanine et de tryptamine", "item": "https://questionsmedicales.fr/mesh/D046948" }, { "@type": "ListItem", "position": 9, "name": "Alcaloïdes de Vinca", "item": "https://questionsmedicales.fr/mesh/D014748" }, { "@type": "ListItem", "position": 10, "name": "Vincristine", "item": "https://questionsmedicales.fr/mesh/D014750" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Vincristine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Vincristine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-11", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Vincristine", "description": "Comment la vincristine est-elle utilisée dans le diagnostic ?\nQuels tests précèdent l'administration de vincristine ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=SEER+Program#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Vincristine", "description": "Quels sont les effets secondaires de la vincristine ?\nLa vincristine cause-t-elle des douleurs ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=SEER+Program#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Vincristine", "description": "Peut-on prévenir les effets secondaires de la vincristine ?\nY a-t-il des recommandations avant le traitement par vincristine ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=SEER+Program#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Vincristine", "description": "Avec quels médicaments la vincristine est-elle souvent combinée ?\nComment la vincristine est-elle administrée ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=SEER+Program#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Vincristine", "description": "Quelles complications peuvent survenir avec la vincristine ?\nLa vincristine peut-elle causer des problèmes cardiaques ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=SEER+Program#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Vincristine", "description": "Qui est à risque d'effets indésirables de la vincristine ?\nLes antécédents médicaux influencent-ils le traitement par vincristine ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=SEER+Program#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment la vincristine est-elle utilisée dans le diagnostic ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "La vincristine n'est pas un outil de diagnostic, mais un traitement pour des cancers diagnostiqués." } }, { "@type": "Question", "name": "Quels tests précèdent l'administration de vincristine ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des examens d'imagerie sont effectués pour évaluer la maladie." } }, { "@type": "Question", "name": "Quels sont les effets secondaires de la vincristine ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent neuropathie, constipation, et fatigue." } }, { "@type": "Question", "name": "La vincristine cause-t-elle des douleurs ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut provoquer des douleurs neuropathiques chez certains patients." } }, { "@type": "Question", "name": "Peut-on prévenir les effets secondaires de la vincristine ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des mesures préventives incluent une surveillance étroite et des médicaments pour les symptômes." } }, { "@type": "Question", "name": "Y a-t-il des recommandations avant le traitement par vincristine ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une évaluation médicale complète est recommandée avant le traitement." } }, { "@type": "Question", "name": "Avec quels médicaments la vincristine est-elle souvent combinée ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle est souvent combinée avec la prednisone et d'autres agents chimiothérapeutiques." } }, { "@type": "Question", "name": "Comment la vincristine est-elle administrée ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "La vincristine est administrée par voie intraveineuse, généralement en cycle." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec la vincristine ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des infections, des troubles neurologiques et des problèmes gastro-intestinaux." } }, { "@type": "Question", "name": "La vincristine peut-elle causer des problèmes cardiaques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Bien que rare, des problèmes cardiaques peuvent survenir, nécessitant une surveillance." } }, { "@type": "Question", "name": "Qui est à risque d'effets indésirables de la vincristine ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les patients âgés et ceux avec des antécédents de neuropathie sont à risque accru." } }, { "@type": "Question", "name": "Les antécédents médicaux influencent-ils le traitement par vincristine ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de maladies neurologiques peuvent affecter le traitement." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 21/02/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Wenjian Yang

3 publications dans cette catégorie

Affiliations :
  • Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Deqing Pei

3 publications dans cette catégorie

Affiliations :
  • Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Cheng Cheng

3 publications dans cette catégorie

Affiliations :
  • Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

William E Evans

3 publications dans cette catégorie

Affiliations :
  • Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Richard H Ho

3 publications dans cette catégorie

Affiliations :
  • Vanderbilt University Medical Center, Nashville, TN.

Sima Jeha

2 publications dans cette catégorie

Affiliations :
  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Ching-Hon Pui

2 publications dans cette catégorie

Affiliations :
  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Mirjam E van de Velde

2 publications dans cette catégorie

Affiliations :
  • Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

Aniek Uittenboogaard

2 publications dans cette catégorie

Affiliations :
  • Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.

Gertjan J L Kaspers

2 publications dans cette catégorie

Affiliations :
  • Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.

Esperanza Herradón

2 publications dans cette catégorie

Affiliations :
  • Departamento de Ciencias Básicas de la Salud, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Alcorcón, Spain.
  • Unidad Asociada al Instituto de Química Medica (IQM) del Consejo Superior de Investigaciones Científicas (CSIC), Universidad Rey Juan Carlos, Alcorcón, Spain.
  • High Performance Research Group in Experimental Pharmacology (Pharmakom-URJC), URJC, Alcorcón, Spain.
Publications dans "Vincristine" :

Visitación López-Miranda

2 publications dans cette catégorie

Affiliations :
  • Departamento de Ciencias Básicas de la Salud, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Alcorcón, Spain.
  • Unidad Asociada al Instituto de Química Medica (IQM) del Consejo Superior de Investigaciones Científicas (CSIC), Universidad Rey Juan Carlos, Alcorcón, Spain.
  • High Performance Research Group in Experimental Pharmacology (Pharmakom-URJC), URJC, Alcorcón, Spain.
Publications dans "Vincristine" :

Yang Li

2 publications dans cette catégorie

Affiliations :
  • Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, PR China.

Jing Huang

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Mental Health Institute of the Second Xiangya Hospital, Central South University, Chinese National Clinical Research Center on Mental Disorders (xiangya), Chinese National Technology Institute on Mental Disorders, Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, Hunan 410011, China.
Publications dans "Vincristine" :

Johnny Donovan

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

Zicheng Deng

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
  • The Materials Science and Engineering Program, College of Engineering and Applied Science, University of Cincinnati, Cincinnati, OH, United States.
  • Center for Lung Regenerative Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

Fenghua Bian

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

Samriddhi Shukla

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

Jose Gomez-Arroyo

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
  • Division of Pulmonary and Critical Care and Sleep Medicine, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, United States.

Donglu Shi

2 publications dans cette catégorie

Affiliations :
  • The Materials Science and Engineering Program, College of Engineering and Applied Science, University of Cincinnati, Cincinnati, OH, United States.

Sources (10000 au total)

The epidemiology and prognosis of patients with primary gastric T-cell lymphoma in the SEER program.

Primary gastric T-cell lymphoma (PG-TCL) is a rare hematological malignancy with few data reported. The objective of this study is to investigate the epidemiology, clinical characteristics, and surviv... Totally, 164 patients with PG-TCL from 1975 to 2016 extracted from the Surveillance, Epidemiology, and End Results Program (SEER) database were analyzed. Kaplan-Meier method was applied to plot overal... The age-adjusted incidence rate of PG-TCL was 0.0091 per 100,000 person-years and increased with age. The median age at onset was 65 years old with male predominance. The major histological type was p... PG-TCL is a rare neoplasm with low incidence. Patients with PG-TCL generally exhibited poor prognosis. Use of chemotherapy plus radiotherapy was associated with favorable OS....

Soft-tissue Sarcoma Survival in the US Military Health System: Comparison With the SEER Program.

The US Military Health System (MHS) provides universal health care to beneficiaries. Few studies have evaluated the potential influence of access to universal care on survival outcomes for sarcoma. Th... MHS data were obtained from the Department of Defense Automated Central Tumor Registry (ACTUR). US population data were obtained from the National Cancer Institute's Surveillance, Epidemiology, and En... Adult patients in ACTUR had markedly lower 5-year mortality for soft-tissue sarcomas (hazard ratio=0.82; 95% confidence interval, 0.73 to 0.92) after adjustment for potential confounders. Lower 5-year... Five-year survival in the MHS compared with the US general population may suggest an important role of universal health care in improving the survival of patients with soft-tissue sarcoma....

Risk prediction of second primary malignancies in patients after rectal cancer: analysis based on SEER Program.

This study will focus on exploring the clinical characteristics of rectal cancer (RC) patients with Second Primary Malignancies (SPMs) and constructing a prognostic nomogram to provide clinical treatm... We determined the association between risk factors and overall survival (OS) while establishing a nomogram to forecast the further OS status of these patients via Cox regression analysis. Finally, we ... Nine parameters were identified to establish the prognostic nomogram in this study, and, the C-index of the training set and validation set was 0.691 (95%CI, 0.662-0.720) and 0.731 (95%CI, 0.676-0.786... We systematically explored the clinical characteristics of SPMs after RC and constructed a satisfactory nomogram....

The impact of individual-level income predicted from the BRFSS on the association between insurance status and overall survival among adults with cancer from the SEER program.

Among patients with cancer in the United States, Medicaid insurance is associated with worse outcomes than private insurance and with similar outcomes as being uninsured. However, prior studies have n... The Surveillance, Epidemiology, and End Results (SEER) database was queried for 18-64 year-old individuals with cancer from 2014-2016. Individual-level income was imputed using a model trained on Beha... A total of 416,784 cases in SEER were analyzed. The 1-yr OS for patients with private insurance, Medicaid insurance, and no insurance was 88.7%, 76.1%, and 73.7%, respectively. After adjusting for all... Income, rather than Medicaid status, may drive poor cancer outcomes in the low-income and Medicaid-insured population. Medicaid insurance coverage may improve cancer outcomes for low-income individual...

Epidemiologic characteristics and a prognostic nomogram for patients with vulvar cancer: results from the Surveillance, Epidemiology, and End Results (SEER) program in the United States, 1975 to 2016.

To elucidate clinical characteristics and build a prognostic nomogram for patients with vulvar cancer.... The study population was drawn from the Surveillance, Epidemiology, and End Results (SEER) database. Patients were randomly assigned to training and validation sets. Cox proportional hazards model and... A total of 20,716 patients were included in epidemiological analysis, of whom 7,025 patients were selected in survival analysis, including 4,215 and 2,810 in training and validation sets, respectively... The nomogram showed accurate prognostic prediction in OS and CSS for vulvar cancer, which could provide guidance to clinical practice....

Malignant pleural mesothelioma characteristics and outcomes: A SEER-Medicare analysis.

Pleural mesothelioma is rare cancer linked to asbestos exposure. Previous research has indicated that female individuals have better survival than male individuals, but this has never been examined in... Malignant pleural mesothelioma cases diagnosed from 1992 to 2015 were queried from the linked SEER-Medicare database. Multivariable logistic regression was used to assess the clinical and demographic ... Among 4201 patients included in the analysis, 3340 (79.5%) were males and 861 (20.5%) females. Females were significantly older, with more epithelial histology than males were, and had significantly b... The study describes sex differences in mesothelioma occurrence, treatment, and survival and is the first to examine SEER-Medicare. It provides directions for future research into potential therapeutic...

Prognostic nomogram in patients with epithelioid sarcoma: A SEER-based study.

The prognostic factors for patients with epithelial sarcoma remain unclear. The study aims to develop a practical clinical nomogram that predicts prognosis in patients with ES using the Surveillance, ... We extracted clinical data from 2004 to 2015 from the SEER database about patients with ES. All patients were randomly divided into training cohort and validation cohort. Kaplan-Meier analyses were us... In the primary cohort,320 met the inclusion criteria to be entered into this study. The median OS was 66.000 months (range 34.704 to 94.296 months), and the 1-, 3-, and 5-year OS rates were 70.7%, 56.... It is the first study that developed an effective survival prediction model for patients with ES. Using this nomogram can assist in clinical decision-making as it has satisfactory accuracy. Even so, a...